➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Mallinckrodt
AstraZeneca
Express Scripts
Johnson and Johnson

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FIDAXOMICIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Fidaxomicin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00314951 ↗ Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018) Completed Optimer Pharmaceuticals LLC Phase 3 2006-05-01 This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).
NCT00468728 ↗ PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Completed Optimer Pharmaceuticals LLC Phase 3 2006-10-01 This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
NCT01552668 ↗ Fidaxomicin to Prevent Clostridium Difficile Colonization Withdrawn Centers for Disease Control and Prevention Phase 4 2012-09-01 The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.
NCT01552668 ↗ Fidaxomicin to Prevent Clostridium Difficile Colonization Withdrawn Washington University School of Medicine Phase 4 2012-09-01 The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.
NCT01591863 ↗ Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) Completed Optimer Pharmaceuticals LLC Phase 2 2012-06-01 The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fidaxomicin

Condition Name

Condition Name for Fidaxomicin
Intervention Trials
Clostridium Difficile Infection 10
Clostridium Difficile 6
Diarrhea 4
Clostridium Difficile Infection (CDI) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fidaxomicin
Intervention Trials
Infection 15
Communicable Diseases 12
Diarrhea 8
Clostridium Infections 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fidaxomicin

Trials by Country

Trials by Country for Fidaxomicin
Location Trials
United States 94
Canada 9
United Kingdom 8
Poland 7
France 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fidaxomicin
Location Trials
California 7
New York 6
Massachusetts 5
Illinois 5
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fidaxomicin

Clinical Trial Phase

Clinical Trial Phase for Fidaxomicin
Clinical Trial Phase Trials
Phase 4 11
Phase 3 8
Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fidaxomicin
Clinical Trial Phase Trials
Recruiting 11
Completed 9
Not yet recruiting 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fidaxomicin

Sponsor Name

Sponsor Name for Fidaxomicin
Sponsor Trials
Optimer Pharmaceuticals LLC 5
Cubist Pharmaceuticals LLC 4
Merck Sharp & Dohme Corp. 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fidaxomicin
Sponsor Trials
Industry 25
Other 24
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
Mallinckrodt
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.